The FDA updated two guidance documents that describe temporary policies for the compounding of certain human drugs during the COVID-19 public health emergency. The updates add morphine sulfate and epinephrine to the list of drugs covered by the guidance documents and are being issued to address shortages and access concerns affecting some drugs urgently needed for hospitalized COVID-19 patients. The guidances that have been updated are:
Hospitals that cannot obtain adequate supplies of FDA-approved drugs and are considering the use of compounded drugs for their hospitalized patients should first contact outsourcing facilities, which are subject to more robust quality standards than state-licensed pharmacies or federal facilities that do not register with FDA as outsourcing facilities.
.png)
No hay comentarios:
Publicar un comentario